tiprankstipranks
Hogy Medical Co Ltd (JP:3593)
:3593

Hogy Medical Co (3593) AI Stock Analysis

1 Followers

Top Page

JP:3593

Hogy Medical Co

(3593)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 5.2)
Rating:55Neutral
Price Target:
Â¥6,857.00
â–²(2.50% Upside)
Action:ReiteratedDate:01/31/26
The score is driven primarily by mixed financial performance: a conservative balance sheet is outweighed by notably weaker TTM margins and a sharp drop in free cash flow. Technicals are supportive with a clear uptrend, but valuation is a major headwind due to an extremely high P/E and modest dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage provides financial flexibility for capex, working capital or downturns. A debt-to-equity around 0.17 means the company can fund operations without heavy interest burden, preserving credit capacity and lowering solvency risk over the medium term.
Negative Factors
Shrinking net profitability
A steep drop in net margin signals weakening earnings power and margin compression that could persist without structural cost or mix changes. Low profitability limits reinvestment capacity and raises sensitivity to demand shocks and input cost inflation.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage provides financial flexibility for capex, working capital or downturns. A debt-to-equity around 0.17 means the company can fund operations without heavy interest burden, preserving credit capacity and lowering solvency risk over the medium term.
Read all positive factors

Hogy Medical Co (3593) vs. iShares MSCI Japan ETF (EWJ)

Hogy Medical Co Business Overview & Revenue Model

Company Description
Hogy Medical Co.,Ltd., together with its subsidiaries, manufactures and sells medical supplies to healthcare facilities in Japan. It offers kit products for surgery applications; all-in-one kits for pre/mid/post-surgery; non-woven products, includ...
How the Company Makes Money
Hogy Medical Co. generates revenue primarily through the sale of its medical devices and diagnostic products, which are distributed to healthcare institutions and practitioners. The company employs a multi-faceted revenue model that includes direc...

Hogy Medical Co Financial Statement Overview

Summary
Mixed fundamentals: a strong, low-leverage balance sheet (debt-to-equity ~0.17) offsets weakening profitability and cash conversion. TTM revenue is slightly down (~-1.4%), net margin is very thin (~1.5%) versus FY2025 (~3.9%), and free cash flow fell sharply (~-71.8% YoY) with low cash conversion (~0.20x net income).
Income Statement
44
Neutral
Balance Sheet
78
Positive
Cash Flow
50
Neutral
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue37.84B39.14B39.10B38.98B36.78B36.50B
Gross Profit12.22B12.62B12.49B15.74B15.42B15.33B
EBITDA7.83B8.75B10.71B9.84B10.25B10.18B
Net Income222.00M1.52B2.80B4.32B4.37B4.96B
Balance Sheet
Total Assets94.48B97.89B100.04B102.18B98.97B105.64B
Cash, Cash Equivalents and Short-Term Investments18.28B22.00B19.42B18.86B14.36B20.55B
Total Debt12.17B13.67B5.82B8.89B10.00B330.00M
Total Liabilities20.00B23.56B13.92B18.50B18.97B9.69B
Stockholders Equity74.47B74.32B86.11B83.61B79.96B95.88B
Cash Flow
Free Cash Flow398.00M6.53B4.49B7.95B5.46B-458.00M
Operating Cash Flow5.86B11.76B7.18B9.27B8.51B6.89B
Investing Cash Flow-4.84B-4.12B-3.33B-2.04B-3.82B-6.99B
Financing Cash Flow-3.88B-5.46B-3.89B-3.14B-11.05B-2.50B

Hogy Medical Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6690.00
Price Trends
50DMA
6677.60
Negative
100DMA
6441.70
Positive
200DMA
5631.50
Positive
Market Momentum
MACD
-5.97
Positive
RSI
46.61
Neutral
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3593, the sentiment is Positive. The current price of 6690 is above the 20-day moving average (MA) of 6651.00, above the 50-day MA of 6677.60, and above the 200-day MA of 5631.50, indicating a neutral trend. The MACD of -5.97 indicates Positive momentum. The RSI at 46.61 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3593.

Hogy Medical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
Â¥9.79T21.8925.14%1.01%8.83%8.63%
73
Outperform
Â¥3.21T25.648.98%1.22%7.68%10.08%
68
Neutral
Â¥954.90B24.3311.64%0.82%13.53%-7.39%
62
Neutral
Â¥266.50B5.594.38%2.03%6.04%733.13%
59
Neutral
Â¥1.75T38.5611.34%1.01%0.42%34.76%
55
Neutral
Â¥143.37B67.810.30%1.31%-2.06%-79.17%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3593
Hogy Medical Co
6,650.00
2,359.34
54.99%
JP:4543
Terumo
2,171.00
-650.97
-23.07%
JP:7747
Asahi Intecc Co
3,599.00
1,343.25
59.55%
JP:7741
HOYA
28,985.00
13,557.32
87.88%
JP:8086
Nipro
1,634.00
339.39
26.22%
JP:7733
Olympus
1,588.50
-232.09
-12.75%

Hogy Medical Co Corporate Events

Hogy Medical Presents Q3 FY03/26 Financial Results Briefing
Jan 29, 2026
Hogy Medical Co., Ltd. held a financial results briefing on January 29, 2026, to present its performance for the third quarter of the fiscal year ending March 2026. While specific figures were not disclosed in the release, the briefing underscores...
Hogy Medical Posts Profit Decline but Maintains Full-Year Outlook and Dividend Plan
Jan 29, 2026
Hogy Medical reported consolidated net sales of ¥28.7 billion for the nine months ended December 31, 2025, a 4.3% year-on-year decline, with operating profit down 38.7% to ¥2.09 billion and profit attributable to owners of parent falling...
Hogy Medical Corrects GMO Share Count in Supportive Tender Offer Notice
Jan 6, 2026
Hogy Medical Co., Ltd. has issued an amendment to its prior notice supporting a tender offer for its shares by TCG2509 Co., Ltd., correcting the disclosed number of shares managed by major shareholder Grantham, Mayo, Van Otterloo Co. LLC (GMO). T...
Hogy Medical Discloses Amendment to Tender Offer Documentation After Share Count Error
Jan 6, 2026
Hogy Medical Co., Ltd. has disclosed that TCG2509 Co., Ltd., the bidder in an ongoing tender offer for Hogy Medical’s common stock, has amended its tender offer documentation to correct clerical errors in the reported number of shares held b...
Hogy Medical Updates Support Statement as Tender Offer Gathers Additional Backing
Dec 25, 2025
Hogy Medical has amended its previously announced statement supporting a tender offer for its shares by TCG2509 Co., Ltd., to reflect that the bidder has now also entered into a tender offer agreement with Grantham, Mayo, Van Otterloo Co. LLC. Th...
TCG2509 Amends Tender Offer Documents for Hogy Medical After New Agreement and Clerical Corrections
Dec 25, 2025
TCG2509 Co., Ltd., which launched a tender offer on December 18, 2025 for the common shares of Hogy Medical Co., Ltd., has submitted an amendment to its tender offer registration statement and related public notice after entering into a tender agr...
Hogy Medical Endorses Carlyle Group Affiliate’s Tender Offer for Privatization
Dec 18, 2025
Hogy Medical’s Board of Directors has approved the tender offer from TCG2509 Co., Ltd., an affiliate of Carlyle Group, which aims to acquire all shares and take the company private by delisting its stock. This strategic move could position t...
Hogy Medical Expresses Support for Privatization via Tender Offer
Dec 18, 2025
Hogy Medical Co., Ltd. has announced its Board of Directors’ approval in support of a tender offer for its shares by TCG2509 Co., Ltd., aiming to take the company private. This move is expected to delist the company’s shares, enabling ...
Hogy Medical Revises Dividend Policy and Ends Shareholder Benefits Amid Tender Offer Developments
Dec 17, 2025
Hogy Medical Co., Ltd. has announced its decision to forgo dividend payments for the current fiscal year and abolish its shareholder benefit program starting from 2027, pending the successful completion of a tender offer for its shares by TCG 2509...
TCG2509 Initiates Tender Offer for Hogy Medical Co., Ltd. Stock
Dec 17, 2025
TCG2509 Co., Ltd. has announced the launch of a tender offer to acquire the common stock of Hogy Medical Co., Ltd. at a price of 6,700 yen per share, with the purchase period set between December 18, 2025, and February 5, 2026. This move could sig...
Hogy Medical Announces Strategic Leadership Changes
Dec 17, 2025
Hogy Medical Co., Ltd. has announced key personnel changes effective January 1, 2026, aimed at enhancing organizational development and strategic leadership. These appointments reflect the company’s focus on bolstering its business administr...
Hogy Medical Considers Privatization Amid Carlyle Discussions
Dec 15, 2025
Hogy Medical Co., Ltd. is in discussions with The Carlyle Group regarding potential privatization to enhance its corporate value. While no official decision has been made, the company is considering a tender offer price of JPY 6,700 per share, and...
Hogy Medical Co. Clarifies Stance on Privatization Reports
Dec 9, 2025
Hogy Medical Co., Ltd. addressed recent media reports about its potential privatization, clarifying that while it is exploring various strategic options to enhance corporate value, no decision has been made regarding privatization. This announceme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 31, 2026